Cargando…

Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma

Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin’s lymphoma characterized by poor prognosis. The complexity of MCL pathogenesis arises from aberrant activities of diverse signaling pathways, including BTK, PI3K–AKT–mTOR and MYC-BRD4. Here, we report that MCL-related signaling pathways can be a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vann, Kendra R., Pal, Dhananjaya, Smith, Audrey L., Sahar, Namood-e, Krishnaiah, Maddeboina, El-Gamal, Dalia, Kutateladze, Tatiana G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760370/ https://www.ncbi.nlm.nih.gov/pubmed/35031886 http://dx.doi.org/10.1186/s43556-021-00066-9

Ejemplares similares

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma
por: Pal, Dhananjaya, et al.
Publicado: (2021)

Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection
por: Vann, Kendra R., et al.
Publicado: (2022)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets
por: Vann, Kendra R., et al.
Publicado: (2020)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron
por: Acharya, Arpan, et al.
Publicado: (2022)

Inhibition of translation and immune responses by the virulence factor Nsp1 of SARS-CoV-2
por: Vann, Kendra R., et al.
Publicado: (2020)

A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia
por: Smith, Audrey L., et al.
Publicado: (2022)

MYC protein stability is negatively regulated by BRD4
por: Devaiah, Ballachanda N., et al.
Publicado: (2020)

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
por: Burgoyne, Adam M., et al.
Publicado: (2020)

Protocol for Biochemical Analysis and Structure Determination of the ZZ Domain of the E3 Ubiquitin Ligase HERC2
por: Liu, Jiuyang, et al.
Publicado: (2020)

Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma
por: Thng, Dexter Kai Hao, et al.
Publicado: (2022)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

Transcriptional regulation of BRD7 expression by Sp1 and c-Myc
por: Liu, Huaying, et al.
Publicado: (2008)

Epigenetic countermarks in mitotic chromosome condensation
por: van Wely, Karel H. M., et al.
Publicado: (2017)

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
por: Liu, Zhuojun, et al.
Publicado: (2021)

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
por: Wang, Lifu, et al.
Publicado: (2020)

Characterization of multiple interactions between the envelope E protein of SARS-CoV-2 and human BRD4
por: Zandian, Mohamad, et al.
Publicado: (2022)

Myc enhances B cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition
por: Moyo, Tamara K., et al.
Publicado: (2017)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
por: Nagel, Daniel, et al.
Publicado: (2015)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

A Combinatorial Code for CPEB-Mediated c-myc Repression
por: Ogami, Koichi, et al.
Publicado: (2023)

Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression
por: Li, Gong-Quan, et al.
Publicado: (2015)

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
por: Otto, C., et al.
Publicado: (2019)

Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway
por: Li, Hongchun, et al.
Publicado: (2022)

BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer
por: Zhao, Ran, et al.
Publicado: (2021)

Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression
por: Hong, Zhe, et al.
Publicado: (2023)

BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling
por: Gu, Chunyan, et al.
Publicado: (2017)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma
por: Gong, Yi, et al.
Publicado: (2017)

Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling
por: Singh, Simar Pal, et al.
Publicado: (2017)

P1207: SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY
por: Debaize, Lydie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_okqeiaefflu6qsgef96v00hte3